Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LIVN Stock Chart & Stats
$62.87
$0.70(1.49%)
At close: 4:00 PM EST
$62.87
$0.70(1.49%)
Day’s Range― - ―
52-Week Range$32.48 - $65.57
Previous CloseN/A
Volume66.13K
Average Volume (3M)627.59K
Market Cap
$3.44B
Enterprise Value$2.73B
Total Cash (Recent Filing)$646.08M
Total Debt (Recent Filing)$486.55M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Feb 25, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding54,605,526
10 Day Avg. Volume623,356
30 Day Avg. Volume627,591
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.90
Price to Sales (P/S)2.00
P/FCF Ratio18.48
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-32.80
Forecast
1Y Price Target
$70.00Price Target Upside11.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3.86
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLIVN's 3Q25 revenue and EPS beat consensus.
Growth PotentialLIVN's growth outlook is supported by drivers such as an ongoing HLM capital cycle, share gains in CP Consumables, and improved clinical data/reimbursement in DRE.
Market ExpansionAnticipated continued progress toward the commercialization of new platforms, notably aura6000 in OSA, is likely to expand LIVN's total addressable market.
Bears Say
Earnings ImpactLIVN plans to commercialize its obstructive sleep apnea device on its own rather than using a partner and expects this to result in a headwind to EPS growth before becoming a tailwind as sales ramp.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $32.48 and its highest was $65.57 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $3.44B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Feb 25, 2026 which is in 59 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Nov 05, 2025. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.919 by $0.191.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.81.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,605,526 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $1.11 in its last earnings report, beating expectations of $0.919. Following the earnings report the stock price went down -5.803%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.00 (11.34% Upside)
$70.00 (11.34% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 401.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.59%
12-Months-Change
Fundamentals
Return on Equity
-17.63%
Trailing 12-Months
Asset Growth
1.41%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
LivaNova's third quarter of 2025 showcased robust organic revenue growth, significant gains in the cardiopulmonary and epilepsy segments, and improved financial metrics. However, challenges remain with component supply constraints affecting expansion and negative impacts from currency and tariff changes. Despite these challenges, the company has raised its full-year guidance, reflecting a positive outlook.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$70.00
▲(11.34% Upside)
Technical Analysis
Artivion
―
Integer Holdings
―
Ufp Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Ownership Overview
0.28% Insiders
29.99% Mutual Funds
30.79% Other Institutional Investors
18.09% Public Companies and
Individual Investors